Company Description
Bluejay Diagnostics, Inc. operates as a medical diagnostics company.
It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.
The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings.
In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform.
Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Nov 10, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Indranil Dey |
Contact Details
Address: 360 Massachusetts Avenue, Suite 203 Acton, Massachusetts 01720 United States | |
| Phone | 844 327 7078 |
| Website | bluejaydx.com |
Stock Details
| Ticker Symbol | BJDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 1704287 |
| CUSIP Number | 095633608 |
| ISIN Number | US0956336087 |
| Employer ID | 47-3552922 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Indranil Dey | Principal Financial, Accounting and Executive Officer, President, Chief Executive Officer and Director |
| Kevin Vance | Chief Commercial Officer |
| Mark W. Feinberg M.D., Ph.D. | Chief Medical Advisor |
| Dr. Mark W. Feinberg M.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2026 | 8-K | Current Report |
| Mar 16, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 11, 2026 | SCHEDULE 13D | Filing |
| Mar 11, 2026 | SCHEDULE 13D | Filing |
| Mar 11, 2026 | SCHEDULE 13D | Filing |
| Mar 6, 2026 | 10-K | Annual Report |
| Mar 6, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 18, 2026 | SCHEDULE 13G | Filing |